TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1 Cancer Research Results

TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1, - Tumor Necrosis Factor Receptor Superfamily Member 25 / Death Receptor 3: Click to Expand ⟱
Source:
Type:

TNFRSF25 - Tumor Necrosis Factor Receptor Superfamily Member 25 / Death Receptor 3

Abbreviation: TNFRSF25, DR3

Alternative Names: Death Receptor 3, APO-3, LARD, TRAMP, WSL-1, TR3

Type: Tumor necrosis factor receptor superfamily member / death receptor / immune signaling receptor

Function: DR3 is a type I transmembrane receptor containing an intracellular death domain. Its principal ligand is TL1A/TNFSF15. DR3 signaling can recruit adaptor proteins including TRADD and activate caspase-dependent apoptosis, necroptosis, NF-κB, JNK, and immune-cell activation pathways.

Cancer: ↕ Context-dependent. DR3 activation can induce apoptosis or necroptosis in cancer cells and can enhance antitumor immune responses. However, DR3 can also activate NF-κB-dependent survival or inflammatory signaling, and certain splice variants have been associated with invasion and metastasis in selected cancers.

Favorable Direction in Cancer: Context-dependent. ↑ DR3 death-signaling can be favorable where it promotes apoptosis or necroptosis, whereas ↓ DR3 signaling may be favorable in tumors where DR3 promotes survival, inflammation, invasion, or metastasis.

Interpretation Note: Do not confuse DR3/TNFRSF25 with DcR3/TNFRSF6B. DcR3 is a soluble decoy receptor and is a distinct target.



Scientific Papers found: Click to Expand⟱
8244- LCA,    Licochalcone A from licorice root, an inhibitor of human hepatoma cell growth via induction of cell apoptosis and cell cycle arrest
- in-vitro, Liver, HepG2
TumCP↓, ROS↑, TumCCA↑, Apoptosis↑, survivin↓, CycB/CCNB1↓, CDK1↓, WEE1↑, P21↑, cycD1/CCND1↑, JNK↑, TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, DR5↑, Casp3↑, Casp8↑, Casp10↑, Fas↑, BAD↑, BAX↑, PUMA↑, PKCδ↓, P70S6K↓, Akt↓,
8235- LCA,    Anticancer effects of licochalcones: A review of the mechanisms
- Review, Var, NA
mt-Apoptosis↑, TumAuto↑, TumCMig↓, LC3‑Ⅱ/LC3‑Ⅰ↑, ATG5↑, ATG7↑, p62↑, CHOP/DDIT3↑, ER Stress↑, UPR↑, ATG3↑, Beclin-1/ATG6↑, ATG16L1↑, PERK↑, ATF4↑, ATP↓, Hif1a↓, GLUT1↓, PDK1 / PDPK1↓, Bcl-xL↓, Bcl-2↓, BAD↑, BAX↑, Casp3↑, survivin↓, EGFR↓, ERK↓, Akt↓, mtDam↑, MMP↓, Cyt‑c↑, Casp↑, MDM2↓, CycB/CCNB1↓, CDC2↓, CDC25↓, TumCCA↑, TumCP↓, Wnt↓, β-catenin/ZEB1↓, Sp1/3/4↓, MMP-10↓, MMP3↓, TumCI↓, Imm↑, PD-L1↓, ROS↑, 4E-BP1↓, eIF2α↓, PI3K↓, mTOR↓, p‑cMET↑, Ca+2↑, RUBCN↓, ATG13↑, TSC1↑, TSC2↑, PRAS40↑, PP2A↑, ULK1/ATG1↑, THEM4/CTMP↑, DR5↑, Fas↑, TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, PKCδ↓, P70S6K↓, VEGF↓, angioG↓, HK2↓, Glycolysis↓, TrxR1↓, APAF1↑, cl‑PARP↑, Bax:Bcl2↑, ABCG2↓, BioEnh↑,
8347- Lut,    Carotenoid Lutein Selectively Inhibits Breast Cancer Cell Growth and Potentiates the Effect of Chemotherapeutic Agents through ROS-Mediated Mechanisms
- in-vitro, BC, NA
TumCG↓, TumCCA↑, selectivity↑, ROS↑, eff↓, P53↑, HSP60/HSPD1↑, cycF↑, CDC25↑, CDK6↑, ANAPC2↑, AURKB↑, GADD45A↑, BAX↑, Casp3↑, CASP4↑, Casp8↑, TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, DR6↑, ChemoSen↑,
8898- MOR,    Molecular mechanism of anti-cancerous potential of Morin extracted from mulberry in Hela cells
- in-vitro, Cerv, HeLa
TumCP↓, TumCCA↑, Apoptosis↑, P53↑, P21↑, WEE1↑, CDK1↓, CDC25↓, survivin↓, CycB/CCNB1↓, Chk2↓, BAX↑, BAD↑, Cyt‑c↑, APAF1↑, Casp9↑, TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, DR5↑, FasL↑, FADD↑, Casp10↑, PARP↑, PI3K↑, Akt↑, mTOR↑, p70S6↑, Diablo↑, Bcl-2↓, Bcl-xL↓, AMPK↓, IAP1↓, NF-kB↓, ROS↑,
8874- MOR,    The anticarcinogenic and anticancer effects of the dietary flavonoid, morin: Current status, challenges, and future perspectives
- Review, Var, NA
AntiCan↑, selectivity↑, *ROS↓, *Inflam↓, *p‑Akt↓, *NF-kB↓, ChemoSen↑, chemoPv↑, *toxicity↓, BioAv↑, BioAv↓, MRP1/ABCC1↝, BioAv↑, PCNA↓, hepatoP↑, NF-kB↓, TNF-α↓, IL6↓, PGE2↓, MMP2↓, MMP9↓, Apoptosis↑, TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, DR5↑, FasL↑, FADD↑, ROS↑, MMP↓, BAX↑, Bcl-xL↓, Casp9↑, Casp3↑, EMT↓, Akt↓, Hippo↑,

Showing Research Papers: 1 to 5 of 5

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 5,   TrxR1↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

CDC2↓, 1,   CDC25↓, 2,   CDC25↑, 1,   HSP60/HSPD1↑, 1,   mtDam↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↓, 1,   ATP↓, 1,   Glycolysis↓, 1,   HK2↓, 1,   PDK1 / PDPK1↓, 1,  

Cell Death(tgid=5) ⓘ

APAF1↑, 2,   Apoptosis↑, 3,   mt-Apoptosis↑, 1,   BAD↑, 3,   BAX↑, 5,   Bax:Bcl2↑, 1,   Bcl-2↓, 2,   Bcl-xL↓, 3,   Casp↑, 1,   Casp10↑, 2,   Casp3↑, 4,   CASP4↑, 1,   Casp8↑, 2,   Casp9↑, 2,   Cyt‑c↑, 2,   Diablo↑, 1,   DR5↑, 4,   FADD↑, 2,   Fas↑, 2,   FasL↑, 2,   IAP1↓, 1,   MDM2↓, 1,   PUMA↑, 1,   survivin↓, 3,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 3,   Akt↑, 1,   p‑cMET↑, 1,   EGFR↓, 1,   ERK↓, 1,   Hippo↑, 1,   JNK↑, 1,   mTOR↓, 1,   mTOR↑, 1,   p70S6↑, 1,   P70S6K↓, 2,   PI3K↓, 1,   PI3K↑, 1,   PKCδ↓, 2,   PP2A↑, 1,   PRAS40↑, 1,   Sp1/3/4↓, 1,   THEM4/CTMP↑, 1,   TSC2↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF4↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↑, 1,   eIF2α↓, 1,   ER Stress↑, 1,   PERK↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG13↑, 1,   ATG16L1↑, 1,   ATG3↑, 1,   ATG5↑, 1,   ATG7↑, 1,   Beclin-1/ATG6↑, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   p62↑, 1,   RUBCN↓, 1,   TumAuto↑, 1,   ULK1/ATG1↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

P53↑, 2,   PARP↑, 1,   cl‑PARP↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

ANAPC2↑, 1,   AURKB↑, 1,   CDK1↓, 2,   CDK6↑, 1,   Chk2↓, 1,   CycB/CCNB1↓, 3,   cycD1/CCND1↑, 1,   cycF↑, 1,   GADD45A↑, 1,   P21↑, 2,   TumCCA↑, 4,   WEE1↑, 2,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

4E-BP1↓, 1,   TumCG↓, 1,   TumCP↓, 3,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

Ca+2↑, 1,   EMT↓, 1,   MMP-10↓, 1,   MMP2↓, 1,   MMP3↓, 1,   MMP9↓, 1,   TSC1↑, 1,   TumCI↓, 1,   TumCMig↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   Hif1a↓, 1,   VEGF↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 1,   MMP↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

DR6↑, 1,   IL6↓, 1,   Imm↑, 1,   NF-kB↓, 2,   PD-L1↓, 1,   PGE2↓, 1,   TNF-α↓, 1,   TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, 5,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 1,   BioAv↓, 1,   BioAv↑, 2,   BioEnh↑, 1,   ChemoSen↑, 2,   eff↓, 1,   MRP1/ABCC1↝, 1,   selectivity↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

EGFR↓, 1,   IL6↓, 1,   PD-L1↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   chemoPv↑, 1,   hepatoP↑, 1,  
Total Targets: 129

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

p‑Akt↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 1,   NF-kB↓, 1,  

Functional Outcomes(tgid=23) ⓘ

toxicity↓, 1,  
Total Targets: 5

Scientific Paper Hit Count for: TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1, - Tumor Necrosis Factor Receptor Superfamily Member 25 / Death Receptor 3
2 Licochalcone A
2 Morin
1 Lutein
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:0  prod#:%  Target#:1789  State#:%  Dir#:2
wNotes=0 sortOrder:rid,rpid

 

Home Page